Fidelity Advisor Biotechnology Fund - Class C (FBTCX)
| Fund Assets | 1.30B |
| Expense Ratio | 1.76% |
| Min. Investment | $0.00 |
| Turnover | 73.00% |
| Dividend (ttm) | 1.44 |
| Dividend Yield | 6.64% |
| Dividend Growth | n/a |
| Payout Frequency | n/a |
| Ex-Dividend Date | Dec 26, 2024 |
| Previous Close | 21.71 |
| YTD Return | 3.04% |
| 1-Year Return | -13.02% |
| 5-Year Return | 12.29% |
| 52-Week Low | 17.04 |
| 52-Week High | 27.16 |
| Beta (5Y) | n/a |
| Holdings | 85 |
| Inception Date | Dec 27, 2000 |
About FBTCX
Fidelity Advisor Biotechnology Fund Class C is a mutual fund that primarily invests in companies within the biotechnology sector. Its central objective is capital appreciation, achieved by allocating at least 80% of its assets to securities of firms engaged in the research, development, manufacture, and distribution of biotechnological products, services, and processes. The fund is notably concentrated in the healthcare industry, focusing on businesses that benefit significantly from advances in biotechnology, such as pharmaceuticals and innovative therapeutic providers. The portfolio often holds a high percentage of assets in its top holdings, which typically include leading biotechnology and pharmaceutical companies. With total assets exceeding $1.3 billion, the fund plays a prominent role in offering investors exposure to the dynamic and innovation-driven field of biotechnology. The fund’s investment style is characterized as “mid-blend,” and it is managed with an emphasis on capturing the growth potential within the sector while balancing risk through diversified holdings of both large and emerging biotech firms. This fund is part of Fidelity’s suite of sector-specific offerings, serving investors seeking targeted access to the biotechnology market.
Performance
FBTCX had a total return of -13.02% in the past year, including dividends. Since the fund's inception, the average annual return has been 5.92%.
Top 10 Holdings
60.00% of assets| Name | Symbol | Weight |
|---|---|---|
| AbbVie Inc. | ABBV | 19.38% |
| Gilead Sciences, Inc. | GILD | 8.75% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 7.26% |
| Ascendis Pharma A/S | ASND | 5.53% |
| Amgen Inc. | AMGN | 5.25% |
| argenx SE | ARGX | 4.92% |
| Neurocrine Biosciences, Inc. | NBIX | 2.63% |
| Nuvalent, Inc. | NUVL | 2.38% |
| Vaxcyte, Inc. | PCVX | 1.99% |
| Viridian Therapeutics, Inc. | VRDN | 1.90% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 26, 2024 | $1.441 | Dec 27, 2024 |
| Dec 17, 2021 | $5.241 | Dec 20, 2021 |
| Jul 9, 2021 | $0.006 | Jul 12, 2021 |
| Dec 18, 2020 | $2.732 | Dec 21, 2020 |
| Dec 20, 2019 | $1.849 | Dec 23, 2019 |
| Dec 7, 2018 | $0.589 | Dec 10, 2018 |